Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of imatinib dose adaptation guided by plasma trough concentration in chronic myeloid leukemia
2008-007094-20Phase 3Terminated
- Sponsor
- Institut Bergonié
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Institut Bergonié. Primary endpoint: BCR-ABL transcript level by RT-PCR. Started Jun 2009; status: terminated.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2008-007094-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007094-20.